Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

doi:10.1200/JCO.2015.62.9345

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2016

Long Georgina V, Weber Jeffrey S, Infante Jeffrey R, Kim Kevin B, Daud Adil, Gonzalez Rene, Sosman Jeffrey A, Hamid Omid, Schuchter Lynn, Cebon Jonathan, Kefford Richard F, Lawrence Donald, Kudchadkar Ragini, Burris Howard A, Falchook Gerald S, Algazi Alain, Lewis Karl, Puzanov Igor, Ibrahim Nageatte, Sun Peng, Cunningham Elizabeth, Kline Amy S, Del Buono Heather, McDowell Diane Opatt, Patel Kiran, Flaherty Keith T

Abstract excerpt

PURPOSE: To report the overall survival (OS) and clinical characteristics of BRAF inhibitor-naive long-term responders and survivors treated with dabrafenib plus trametinib in a phase I and II study of patients with BRAF V600 mutation-positive metastatic melanoma. METHODS: BRAF inhibitor-naive patients treated with dabrafenib 150 mg twice daily plus trametinib 2 mg daily (the 150/2 group) from the non-randomly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Melanoma

Share to Neoplasm Metastasis

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 26811525
DOI: 10.1200/JCO.2015.62.9345

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.PMID 26811525Read ↗

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Semantic proximity Read ↗

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.Semantic proximity Read ↗

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.Semantic proximity Read ↗

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Semantic proximity Read ↗

Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.Semantic proximity Read ↗

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.